ProQR Therapeutics (PRQR) Fundamental Analysis: Revenue, Earnings & Valuation

4.10 / 10

Netural

Fundamental score is 4.1/10, indicating fair health. Strengths include strong Revenue‑MV, Cash‑MV and inventory turnover, while fixed‑asset turnover, YoY revenue decline (‑15.9%) and low income‑tax‑to‑profit hurt the profile. Overall, the fundamentals are neutral with modest upside.

Analysis Checks(7/10)

Revenue-MV

Value-2.06

Score2/3

Weight19.24%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value-15.86

Score2/3

Weight-1.89%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight15.69%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.58%

1M Return1.69%

PB-ROE

Value0.86

Score1/3

Weight13.14%

1M Return5.29%

Income tax / Total profit (%)

Value-0.05

Score1/3

Weight-0.90%

1M Return-0.50%

Fixed assets turnover ratio

Value1.19

Score1/3

Weight-2.19%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.07%

1M Return4.32%

Asset-MV

Value-0.55

Score2/3

Weight30.33%

1M Return12.22%

Cash-MV

Value0.02

Score2/3

Weight13.93%

1M Return5.94%

Is PRQR fundamentally strong?

PRQR scores 4.10/10 on fundamentals and holds a Fair valuation at present. Backed by its -61.17% ROE, -265.21% net margin, -3.64 P/E ratio, 3.11 P/B ratio, and -41.73% earnings growth, these metrics solidify its Netural investment rating.